Beverly Kyalwazi, Christina Yau, Michael J Campbell, Toshio F Yoshimatsu, A Jo Chien, Anne M Wallace, Andres Forero-Torres, Lajos Pusztai, Erin D Ellis, Kathy S Albain, Anne H Blaes, Barbara B Haley, Judy C Boughey, Anthony D Elias, Amy S Clark, Claudine J Isaacs, Rita Nanda, Hyo S Han, Rachel L Yung, Debasish Tripathy, Kristen K Edmiston, Rebecca K Viscusi, Donald W Northfelt, Qamar J Khan, Smita M Asare, Amy Wilson, Gillian L Hirst, Ruixiao Lu, William Fraser Symmans, Douglas Yee, Angela M DeMichele, Laura J van 't Veer, Laura J Esserman, Olufunmilayo I Olopade
IMPORTANCE: There has been little consideration of genomic risk of recurrence by breast cancer subtype despite evidence of racial disparities in breast cancer outcomes. OBJECTIVE: To evaluate associations between clinical trial end points, namely pathologic complete response (pCR) and distant recurrence-free survival (DRFS), and race and examine whether gene expression signatures are associated with outcomes by race. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from the Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2 (I-SPY 2) multicenter clinical trial of neoadjuvant chemotherapy with novel agents and combinations for patients with previously untreated stage II/III breast cancer...
December 1, 2023: JAMA Network Open